Mithra’s Marketing Authorization Application for Tibelia® Accepted by Health Canada

  • Tibelia® would be the first tibolone-based Hormone Therapy product available in Canada
  • Marketing Authorization (MA) decision in Canada expected as of Q4 2018
  • Mithra’s Canadian partner preparing for potential launch shortly thereafter

Liège, Belgium, 10 October 2017 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces that Health Canada has accepted the Marketing Authorization Application for its complex therapeutic Tibelia®, the company’s tibelone-based product for use in Hormone Therapy (HT).